PL3851441T3 - Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu - Google Patents
Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamiduInfo
- Publication number
- PL3851441T3 PL3851441T3 PL20209166.6T PL20209166T PL3851441T3 PL 3851441 T3 PL3851441 T3 PL 3851441T3 PL 20209166 T PL20209166 T PL 20209166T PL 3851441 T3 PL3851441 T3 PL 3851441T3
- Authority
- PL
- Poland
- Prior art keywords
- oxooxazolidin
- oxazepin
- dihydrobenzo
- propanamide
- imidazo
- Prior art date
Links
- SGEUNORSOZVTOL-CABZTGNLSA-N (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide Chemical compound FC([C@H]1N(C(OC1)=O)C=1N=C2N(CCOC3=C2C=CC(=C3)N[C@H](C(=O)N)C)C=1)F SGEUNORSOZVTOL-CABZTGNLSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662434836P | 2016-12-15 | 2016-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3851441T3 true PL3851441T3 (pl) | 2023-11-06 |
Family
ID=61027659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20209166.6T PL3851441T3 (pl) | 2016-12-15 | 2017-12-15 | Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu |
| PL17835634T PL3555107T3 (pl) | 2016-12-15 | 2017-12-15 | Sposób wytwarzania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17835634T PL3555107T3 (pl) | 2016-12-15 | 2017-12-15 | Sposób wytwarzania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10781219B2 (pl) |
| EP (2) | EP3555107B1 (pl) |
| JP (1) | JP7004720B2 (pl) |
| KR (1) | KR102537048B1 (pl) |
| CN (1) | CN110088111B (pl) |
| AR (1) | AR110527A1 (pl) |
| AU (2) | AU2017378188B2 (pl) |
| CA (1) | CA3044500A1 (pl) |
| ES (2) | ES2953833T3 (pl) |
| HR (2) | HRP20210592T1 (pl) |
| HU (1) | HUE062517T2 (pl) |
| IL (2) | IL267265B (pl) |
| MX (2) | MX377921B (pl) |
| PL (2) | PL3851441T3 (pl) |
| SG (1) | SG10201913961PA (pl) |
| SI (1) | SI3555107T1 (pl) |
| TW (1) | TWI770093B (pl) |
| WO (1) | WO2018109204A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202108592A (zh) | 2015-07-02 | 2021-03-01 | 瑞士商赫孚孟拉羅股份公司 | 苯并氧氮呯噁唑啶酮化合物及其用途 |
| EP4534148A3 (en) | 2017-04-28 | 2025-05-21 | F. Hoffmann-La Roche AG | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
| MX2022002415A (es) | 2019-08-26 | 2022-03-22 | Arvinas Operations Inc | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. |
| AU2020389670A1 (en) * | 2019-11-25 | 2022-05-19 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof |
| WO2021177945A1 (en) * | 2020-03-03 | 2021-09-10 | Momentive Performance Materials Inc. | Catalyst composition |
| CA3220273A1 (en) | 2021-05-28 | 2022-12-01 | Genentech, Inc. | Process for the preparation of benzoxazepin oxazolidinone compounds |
| TW202440096A (zh) | 2023-03-24 | 2024-10-16 | 美商亞文納營運公司 | 雌激素受體降解劑之給藥方案 |
| WO2025016888A1 (en) * | 2023-07-14 | 2025-01-23 | F. Hoffmann-La Roche Ag | C-N COUPLING PROCESS WITH [CU 2(µ-SALBEN) 2] COMPLEXES |
| WO2025036856A1 (en) | 2023-08-11 | 2025-02-20 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation comprising a coated tablet |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20121025A1 (es) | 2009-09-28 | 2012-08-06 | Hoffmann La Roche | Compuestos de benzoxazepina como inhibidores de la p13k |
| CA2825966A1 (en) | 2011-03-21 | 2012-09-27 | F. Hoffmann-La Roche Ag | Benzoxazepin compounds selective for pi3k p110 delta and methods of use |
| EP3404032B1 (en) | 2013-03-13 | 2025-07-02 | F. Hoffmann-La Roche AG | Process for making benzoxazepin compounds |
| TW202108592A (zh) | 2015-07-02 | 2021-03-01 | 瑞士商赫孚孟拉羅股份公司 | 苯并氧氮呯噁唑啶酮化合物及其用途 |
| EP4534148A3 (en) | 2017-04-28 | 2025-05-21 | F. Hoffmann-La Roche AG | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production |
-
2017
- 2017-12-15 PL PL20209166.6T patent/PL3851441T3/pl unknown
- 2017-12-15 CA CA3044500A patent/CA3044500A1/en active Pending
- 2017-12-15 KR KR1020197020323A patent/KR102537048B1/ko active Active
- 2017-12-15 HR HRP20210592TT patent/HRP20210592T1/hr unknown
- 2017-12-15 SI SI201730711T patent/SI3555107T1/sl unknown
- 2017-12-15 HU HUE20209166A patent/HUE062517T2/hu unknown
- 2017-12-15 MX MX2019006958A patent/MX377921B/es unknown
- 2017-12-15 CN CN201780078083.8A patent/CN110088111B/zh active Active
- 2017-12-15 AR ARP170103528A patent/AR110527A1/es unknown
- 2017-12-15 HR HRP20230948TT patent/HRP20230948T1/hr unknown
- 2017-12-15 JP JP2019531931A patent/JP7004720B2/ja active Active
- 2017-12-15 ES ES20209166T patent/ES2953833T3/es active Active
- 2017-12-15 SG SG10201913961PA patent/SG10201913961PA/en unknown
- 2017-12-15 WO PCT/EP2017/083143 patent/WO2018109204A1/en not_active Ceased
- 2017-12-15 ES ES17835634T patent/ES2867389T3/es active Active
- 2017-12-15 TW TW106144193A patent/TWI770093B/zh active
- 2017-12-15 AU AU2017378188A patent/AU2017378188B2/en active Active
- 2017-12-15 PL PL17835634T patent/PL3555107T3/pl unknown
- 2017-12-15 EP EP17835634.1A patent/EP3555107B1/en active Active
- 2017-12-15 EP EP20209166.6A patent/EP3851441B1/en active Active
-
2019
- 2019-06-12 IL IL267265A patent/IL267265B/en active IP Right Grant
- 2019-06-13 MX MX2020010948A patent/MX2020010948A/es unknown
- 2019-06-14 US US16/441,765 patent/US10781219B2/en active Active
-
2021
- 2021-02-17 AU AU2021201046A patent/AU2021201046A1/en not_active Abandoned
- 2021-02-24 IL IL281087A patent/IL281087A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281087A (en) | Process for preparing (S)-2-((2-((S)-4-(difluoromethyl)-2-oxoxazolidine-3-YL)-6,5-dihydrobenzo[F]imidazo[2,1-D][4 , 1]oxazapine-9-YL)amino)propanamide | |
| IL267464A (en) | Polymorphs and solid forms of (s)-2-((2-((s-4-(difluoromethyl)-2-oxoxolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][ 1,4]oxazepin-9-yl)amino)propanamide and methods of production | |
| IL266170A (en) | A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts | |
| IL276917A (en) | A process for the preparation of alubixivet | |
| SI3097098T1 (sl) | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina | |
| IL288080A (en) | A process for the preparation of h7-pyrrolo[3,2-d]pyrimidine derivatives and their artificial intermediates | |
| SG10202110927VA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| IL260999B (en) | A method for the preparation of a pyrrolo[3,2-d] pyrimidine compound, and its intermediates | |
| IL260465B (en) | A process for preparing an antibody-rifamycin conjugate | |
| HUE063118T2 (hu) | Eljárás N-alkil-nitrátoetilnitraminok elõállítására | |
| EP3405456A4 (en) | PROCESS FOR THE PREPARATION OF 4-ALKOXY-3-ACETOXYPICOLINIC ACIDS | |
| IL281254A (en) | A process for the preparation of lanbatinib | |
| IL248965A0 (en) | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazapine-9-yl)-2-methylpropanamide, preparation methods and their pharmaceutical uses | |
| EP3422855A4 (en) | PROCESS FOR THE PREPARATION OF 4-ALKOXY-3-HYDROXYPICOLIC ACIDS | |
| PL3599256T3 (pl) | Sposób wytwarzania poliorganosiloksanów | |
| HUE058725T2 (hu) | Eljárás aminok elõállítására | |
| AU2018297073A1 (en) | Process for the preparation of morphinane compounds | |
| HUP1800278A2 (en) | Process for the preparation of boc-linagliptin | |
| IL268103A (en) | A process for the preparation of chiral pyrrolidine-2-yl-methanol derivatives | |
| HUP1800397A2 (en) | Process for the preparation of lumateperone and salts thereof | |
| PL3510031T3 (pl) | Sposób wytwarzania 2-(6-nitropirydyn-3-ylo)-9H-dipirydo[2,3-b;3',4'-d]pirolu |